2018 has all the action right now and I want to see if there is any interest at all in the 2019 (which has more interest lol)
2018 had some small trades for 45% of par while the 2019 has an offer for 17% of par.
Actually I am kind of with Ultra here. I would like to see TC buying the bonds cheap from weak hands because it makes my bonds much more valuable. If TC were to buy up half of all the bonds at under 40% then it is very likely the remaining bonds would eventually reach 100%.
FR100%+ is not extremely rare (if it was, then the population Endocyte can treat would be too small to be worthwhile). It is possible we just got unlucky and there are no FR100%+ expressing tumors in the types of cancers EC1456 is best at targeting. Or perhaps it just takes longer at MDT than we have had so far.
There is also a chance we have some partial responses but they have not been disclosed yet.
Still a good opportunity to make at least a 200% return (100% of par plus maybe three more quarters of interest payments)
14% of par was so nice....sigh.
I didn't see much trade on the 2019 notes today and a little bit of trade on the 2018. I expected a bit more trading on them considering TC was up 20%.
Even if TC were buying them at 50% it would be a good deal, so no need to worry yet. When they refinance, they will have to pay 100%. That is where I am going to make my money.
First, Do has wife and girlfriend, while Ultra is too ugly even for a date.
Second, and this is the real reason. Ultra has a defective gene (jean?) that does not allow him to use the proper version of they're, their, there and Do does not have this gene. If you look at Do's posts, while they do exhibit purposely poor grammar, to my knowledge he has never mixed his theirs.
Good points, but the only caveat here is I would like to see some partial responses (complete response would be great but that is pie in the sky) as we are well into the dose range that should be able to do this. I do realize that people were not screened for FR+ but still, the odds say we should see a few PR if not a CR out of the entire group of MDT testing.
I think all we have right now that they have released is SD, which by itself won't get us to $60.
Ok, notes, not bonds. It is very hard to refer to them as notes when Etrade calls them bonds and I buy them on the Etrade bond desk.
Hah, how can you day trade these when there are days that the volume is zero?
The only similar stock that I was in was Claude and it already did the multi-bagger thing and got bought out.
The other stock I am in that will one day likely be a multi-bagger is Endocyte. It is a biotech developing a cure for some cancers by attaching a lethal drug to a molecule that allows it to travel through the body without damaging other tissue. It is $4 right now (was $3) and has $3.50 to $4 in cash. If they partner up or get bought out, it will be in the $30 to $40 range. I only have 10,000 shares of it, but at $30 it would be a nice little return.
Half of the posts now between Ultra and Do are political and 50% of the rest are arguments about Bernie's real ID.
Any actual, I don't know, information about TC?
"But Light, you must admit the stock is the better investment"
Just teasing you gatr55. Hope you are doing well from your surgery.
Wish we both had bought more bonds.
You need a full crew for a yacht of that size. Most likely we will buy something in the 38 to 42 foot range for blue water cruising.
I wish I had listened to the advice I was giving everyone here to buy the 2019 bonds when they were 18% of par (and the 2018 at 14%). I bought a little more but I should have bought huge. I just didn't have the ready cash like I do now (sold house).
This is the kind of opportunity that makes multi millionaires out of millionaires.
Bonds seem to be going up. The secured is hitting 98 and nobody is selling unsecured for lower than 34.
If they bought $150m, I hope they did it a few weeks back instead of now.
Imagine back a few weeks ago when you could buy $1000 of bonds for $180 and get paid $125 a year.
From the poster on Endocyte's investor page:
"This agent was found to be extremely potent with an in vitroIC50 ~ 100 x lower than any other
folate SMDC we have created to date. Treatment of nude mice bearing FR positive human xenografts
led to cures in 100% of the mice at very low doses ( 500 nmol/kg) and a convenient once a week schedule. The observed activity was not accompanied by any noticeable weight loss (up to 20 weeks post end of dosing) or major organ tissue degeneration. In contrast, no significant anti-tumor activity (0% CRs) was observed in treated animals that were co-dosed with an excess of a benign folateligand, thus demonstrating its target-specific activity. Complete responses were also observed in other FR positive drug resistant (paclitaxel and ciplatin) models. "